Antimicrobial Agents and Chemotherapy, February 1999, p. 226-232, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Department of Medical Microbiology,
Received 22 April 1998/Returned for modification 18 August
1998/Accepted 2 November 1998
We investigated the relationship between susceptibility to
-lactam antibiotics and variation in the major outer membrane protein P2 (OmpP2; also called porin) of persistent nonencapsulated Haemophilus influenzae isolated from cystic fibrosis
patients. Nine OmpP2 variants were selected from two distinct
H. influenzae strains from two patients extensively
treated with
-lactam antibiotics. The variants differed in their
susceptibilities to at least two
-lactam antibiotics. By detergent
extraction and column chromatography, OmpP2 was purified from two
variants that were derived from strain 70 and that differed notably in
their susceptibilities to
-lactam antibiotics. The proteins were
reconstituted into black lipid membranes for measurement of porin
function. OmpP2 from the more resistant isolate (isolate 70b) had a
smaller channel conductance than OmpP2 of the more susceptible isolate
(isolate 70f). DNA sequencing of ompP2 of these isolates
revealed single nonsynonymous base differences; there were changes
in the amino acid sequence corresponding to surface-exposed loops 4, 5, 6, and 8. Changes in loops 4, 5, and 6 were previously shown to result
in antigenic differences. Beside these mutations, variants of strain 70 showed additional mutations in loop 1 and nonexposed loop 3. Taken
together, our results suggest that in variants of strain 70, nonsynonymous point mutations accumulated both in the sequences of
ompP2 coding for antigen-variable loops and in other loops,
notably, loops 1 and 3. The latter changes are suggested to affect the
permeability of the porin channel.
*
Corresponding author. Mailing address: Laboratory for
Vaccine Research (LVR), P.O. Box 1, NL-3720 BA Bilthoven, The
Netherlands. Phone: 31-20-2742701. Fax: 31-30-2744429. E-mail:
Loek.van.Alphen{at}rivm.nl.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |